Cancer Genetics Overview
- Founded
- 1999
- Status
- Public
- Employees
- 110
- Stock Symbol
- CGIX
- Investments
- 5
- Share Price
- $4.21
- (As of Friday Closing)
Cancer Genetics General Information
Description
Cancer Genetics Inc through its vivoPharm subsidiary offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages, valued by the pharmaceutical industry, biotechnology companies, and academic research centers. The company is focused on precision and translational medicine to drive drug discovery and novel therapies. Its subsidiary, vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings. VivoPharm operates in The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited facilities.
Contact Information
Primary Industry
Pharmaceuticals
Stock Exchange
NAS
Primary Office
- 201 Route 17 North
- 2nd Floor
- Rutherford, NJ 07070
- United States
+1 (201) 000-0000
Cancer Genetics Timeline
Cancer Genetics Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.21 | $4.30 | $1.92 - $10.39 | $17.2M | 4.09M | 696K | -$1.94 |
Cancer Genetics Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 | FY 2017 31-Dec-2017 |
|---|---|---|---|---|
| EV | 7,824 | 13,085 | 17,350 | 54,471 |
| Revenue | 6,329 | 7,305 | 4,932 | 29,121 |
| EBITDA | (3,057) | (5,311) | (3,106) | (18,729) |
| Net Income | (4,525) | (6,708) | (20,373) | (20,880) |
| Total Assets | 9,690 | 14,904 | 35,406 | 52,221 |
| Total Debt | 180 | 1,655 | 2,580 | 11,033 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Cancer Genetics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Cancer Genetics‘s full profile, request access.
Request a free trialCancer Genetics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is available in the PitchBook Platform. To explore Cancer Genetics‘s full profile, request access.
Request a free trialCancer Genetics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Cancer Genetics Inc through its vivoPharm subsidiary offers proprietary preclinical test systems supporting clinical dia
Pharmaceuticals
Rutherford, NJ
110
As of 2019
000.00
000000000
000.00
000000
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatu
0000 000000000
Princeton, NJ
000
As of 0000
00000
0000
0000-00-00
000000&0
00000
000 0000
sse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in
0000 000000000
Newark, DE
0000
As of 0000
000000000 -
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialCancer Genetics Competitors (26)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aptuit | Formerly PE-Backed | Princeton, NJ | 000 | 00000 | 000000&0 | 00000 |
| 000 00000000 | Formerly PE-Backed | Newark, DE | 0000 | 000000000 - | ||
| 00000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000&0 | 00000 |
| 00000000 | Corporation | Boston, MA | 0 | 000.00 | 000000000 | 000.00 |
| 00000000000 | Formerly VC-backed | Portland, OR | 000 | 000.00 | 000000&0 | 000.00 |
Cancer Genetics Executive Team (15)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| John Roberts | Chief Executive Officer, President, Principal Financial Officer and Principal Accounting Officer | ||
| Glenn Miles | Chief Financial Officer |
Cancer Genetics Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Edmund Cannon | Self | Board Member | 000 0000 |
| Franklyn Prendergast MD | Self | Board Member | 000 0000 |
Cancer Genetics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialCancer Genetics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore Cancer Genetics‘s full profile, request access.
Request a free trialCancer Genetics Acquisitions (5)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 | 24-Aug-2020 | 000000000000000000 | Biotechnology | 0000 0000000 | |
| 000000000 | 15-Aug-2017 | 000000000000000000 | 00.00 | Other Pharmaceuticals and Biotechnology | 00000 000000 |
| 00000000 00000000 | 09-Oct-2015 | 000000000000000000 | 000.00 | Diagnostic Equipment | 000000 00000 |
| 0000000 | 16-Jul-2014 | 000000000000000000 | 00.000 | Practice Management (Healthcare) | 00000 000000 |
| Cancer Genetics India | 15-May-2014 | Merger/Acquisition | 00.00 | Laboratory Services (Healthcare) | 00000 000000 |
Cancer Genetics Subsidiaries (2)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| vivoPharm | Other Pharmaceuticals and Biotechnology | Bundoora, Australia | 2003 |
| 0000000 | Practice Management (Healthcare) | Morrisville, NC | 0000 |
Cancer Genetics Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 000000 00000000 00 | 15-May-2014 | 000000000000000000 | 00.00 | Completed |
|